- In April 2024, Dermavant Sciences announced positive Phase II clinical trial results for a novel topical immunomodulator targeting localized inflammatory skin conditions that often follow Blaschko’s lines, such as lichen striatus and linear psoriasis. The therapy demonstrated promising safety and efficacy profiles, offering a new potential treatment avenue for patients with mosaic dermatological disorders. This development reinforces Dermavant's commitment to advancing innovative topical therapies for rare and underserved skin conditions
- In March 2024, LEO Pharma partnered with a leading genetic research institute to explore RNA-based therapies for skin disorders associated with Blaschko’s lines. This strategic collaboration focuses on gene expression modulation and targeted intervention strategies for congenital and autoimmune dermatological conditions. The initiative highlights the growing role of genomics and precision medicine in dermatology and the increasing emphasis on understanding skin development pathway
- In March 2024, Galderma launched a clinician-led awareness campaign across Europe, aimed at improving early detection and diagnosis of rare dermatoses following Blaschko’s lines. This initiative includes continuing medical education (CME) programs and diagnostic training workshops for dermatologists and general practitioners. The campaign underscores Galderma's efforts to bridge the gap between rare disease presentation and timely, appropriate treatment in clinical settings
- In February 2024, Amryt Pharma initiated a global registry program for patients with skin conditions that exhibit Blaschko-linear distribution, including epidermal nevi and segmental dermatoses. This real-world data collection initiative aims to better understand disease prevalence, treatment patterns, and therapeutic outcomes, supporting future drug development and regulatory approvals. The registry reflects the industry’s growing reliance on patient-centric data to improve care for rare skin disorders
- In January 2024, Bausch Health Companies Inc. expanded the market presence of its advanced topical retinoid therapy in Asia-Pacific, targeting pediatric and adult patients with Blaschko-aligned dermatoses. With enhanced formulation stability and lower irritation potential, the product caters to the rising demand for non-invasive and effective treatments. This expansion illustrates the company’s strategic focus on rare dermatological segments and emerging markets with unmet medical needs
